Kairos Pharma Wins 2025 Clinical Trials Arena Research and Development Excellence Award for Advanced Prostate Cancer

About this update from Kairos Pharma, Ltd.

[{"type":"text","content":"Company recognized for advancing ENV‑105, a first‑in‑class resistance‑modulating antibody for metastatic castration‑resistant prostate cancer","length":141,"tagName":"p","attribs":{}},{"type":"text","content":"LOS ANGELES, December 17, 2025--(BUSINESS WIRE)--Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announced that it has been selected as a winner of the 2025 Clinical Trials Arena Excellence Awards, receiving the Research and Development Award for Advanced Prostate Cancer.","length":358,"tagName":"p"},{"type":"text","content":"Kairos earned this recognition for its work advancing ENV‑105 (carotuximab), a first‑in‑class CD105‑targeting monoclonal antibody designed to modulate resistance pathways in metastatic castration‑resistant prostate cancer (mCRPC). ENV‑105 is being developed as a resistance‑focused therapy intended to restore and extend tumor sensitivity to hormone‑based treatments in patients whose disease has progressed after standard androgen receptor inhibitor therapy.","length":459,"tagName":"p"},{"type":"text","content":"This year, Kairos announced positive interim safety and efficacy results for its Phase 2 randomized clinical trial of ENV-105 in combination with apalutamide in patients with advanced metastatic prostate cancer. Despite progression on prior hormonal therapies, the trial showed clinical benefit when combining ENV-105 with apalutamide in 86% of treated patients to date. All responders remained progression-free for at least four months, and half remained progression-free beyond one year. As of the date of this press release, ENV-105 has not been approved as safe or effective by the United States Food and Drug Administration or any other comparable foreign regulator.","length":671,"tagName":"p"},{"type":"text","content":""Receiving this recognition from Clinical Trials Arena underscores the importance of directly addressing treatment resistance in advanced prostate cancer," said Kairos Pharma Chief Executive Officer Dr. John Yu. "Rather than cycling patients through successive therapies with diminishing benefit, our approach with ENV‑105 is designed to target the underlying biology that allows tumors to adapt and survive. The emerging clinical data support the potential of this strategy to meaningfull...

More updates from Kairos Pharma, Ltd.